New AI Tool Boosts Accuracy in HER2-Low and HER2-Ultralow Breast Cancer Scoring

27 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Marina De Brot, MD, PhD, of A.C. Camargo Cancer Center, in Sao Paulo, Brazil, talks about a new AI-assisted training platform designed to improve HER2 IHC interpretation, particularly for HER2-low and HER2-ultralow breast cancer. Developed through a collaboration between AstraZeneca and Mindpeak, the platform demonstrated significantly improved accuracy and sensitivity among pathologists across global master classes. The AI system offers decision support at the individual tumor cell level, enhancing reproducibility, minimizing misclassification, and potentially expanding patient access to HER2-targeted antibody-drug conjugates. Dr. De Brot explains how this technology works and why it could be a game changer in biomarker training and precision oncology.

#cancer #cancerresearch #oncology #breastcancer #her2positive
Categoria
Oncology
Commenta per primo questo video.

Prossimo